[go: up one dir, main page]

GB202216028D0 - Methods of treatment of melanocytic disease - Google Patents

Methods of treatment of melanocytic disease

Info

Publication number
GB202216028D0
GB202216028D0 GBGB2216028.7A GB202216028A GB202216028D0 GB 202216028 D0 GB202216028 D0 GB 202216028D0 GB 202216028 A GB202216028 A GB 202216028A GB 202216028 D0 GB202216028 D0 GB 202216028D0
Authority
GB
United Kingdom
Prior art keywords
treatment
methods
melanocytic
disease
melanocytic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2216028.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Francis Crick Institute Ltd
Original Assignee
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis Crick Institute Ltd filed Critical Francis Crick Institute Ltd
Priority to GBGB2216028.7A priority Critical patent/GB202216028D0/en
Publication of GB202216028D0 publication Critical patent/GB202216028D0/en
Priority to PCT/EP2023/080145 priority patent/WO2024089274A2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
GBGB2216028.7A 2022-10-28 2022-10-28 Methods of treatment of melanocytic disease Pending GB202216028D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2216028.7A GB202216028D0 (en) 2022-10-28 2022-10-28 Methods of treatment of melanocytic disease
PCT/EP2023/080145 WO2024089274A2 (en) 2022-10-28 2023-10-27 Methods of treatment of melanocytic disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2216028.7A GB202216028D0 (en) 2022-10-28 2022-10-28 Methods of treatment of melanocytic disease

Publications (1)

Publication Number Publication Date
GB202216028D0 true GB202216028D0 (en) 2022-12-14

Family

ID=84839319

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2216028.7A Pending GB202216028D0 (en) 2022-10-28 2022-10-28 Methods of treatment of melanocytic disease

Country Status (2)

Country Link
GB (1) GB202216028D0 (en)
WO (1) WO2024089274A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US11845934B2 (en) * 2016-08-17 2023-12-19 DiaCarta Inc. Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency

Also Published As

Publication number Publication date
WO2024089274A3 (en) 2024-06-20
WO2024089274A2 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
ZA202210984B (en) Methods of treating coronavirus disease 2019
EP4284383A4 (en) Methods of probiotic treatment to improve human health
GB202216028D0 (en) Methods of treatment of melanocytic disease
IL315503A (en) Methods of treatment
IL304628A (en) Treatment of skin disorders
GB202201819D0 (en) Methods of treatment
GB202315831D0 (en) Treatment of skin disease
GB202404416D0 (en) Treatment of disease
GB2618915B (en) Treatment of cardiovascular disease
GB202206359D0 (en) Treatment of pain
GB202201825D0 (en) Methods of treatment
GB202201824D0 (en) Methods of treatment
AU2021903178A0 (en) Treatment of VEGFA-Related Disease
GB202315695D0 (en) TReatment of cariomyopathy
AU2020903576A0 (en) Treatment of VEGFA-Related Disease
GB202212506D0 (en) Treatment of covid-19
GB202207239D0 (en) Treatment of cardiovascular disease 2
GB202116774D0 (en) Treatment of pain
GB202116795D0 (en) Treatment of visceral pain
GB202415658D0 (en) Methods of treatment
GB202211632D0 (en) Treatment of water
GB202407076D0 (en) Methods of treatment
GB202407069D0 (en) Methods of treatment
GB202001353D0 (en) Treatment of skin conditions
GB202301306D0 (en) Treatment of granulomatous disease